Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1301 - Utility of Gallium-68 PSMA PET/CT Scan for Staging and Treatment of Prostate Cancer in Contemporary Era: Study from Tertiary Care Cancer Centre in a Developing Country


24 Nov 2018


Poster display - Cocktail


Alok Gupta


Annals of Oncology (2018) 29 (suppl_9): ix67-ix73. 10.1093/annonc/mdy434


A. Gupta, S.M. Hussain, P. Ahluwalia, G. Gautam, A. Punnakal, H. Chaturvedi, A. Rajput, J. Bal, P. Dougall

Author affiliations

  • Medical Oncology, Max Institute of Cancer Care, 110024 - New Delhi/IN


Abstract 1301


Conventional imaging modalities including bone scan and CT scan have limited sensitivity and specificity compared to 68Ga-PSMA PET/CT scan in detection of metastatic prostate cancer. We analyzed the utility of 68Ga-PSMA PET/CT scan in staging and treatment decision making of prostate cancer at our Institute.


We retrospectively collected data of 330 prostate cancer patients treated between January 2015 and December 2017 at our institute. Patients with intermediate/high risk localized disease and regional lymph node positive disease on MRI, and those with suspected metastatic disease clinically underwent 68Ga-PSMA PET/CT scan. Overall, 168 patients who underwent baseline 68Ga-PSMA PET/CT scan were included in this study.


Median age was 67 years (range 30-88) and median PSA was 30 ng/ml (range 1-4000). Gleason score was <7, 7 and >7 in 5, 56 and 93 patients, respectively. Radiological assessment by 68Ga-PSMA PET/CT scan revealed T2, T3 and T4 lesion in 19, 98 and 51 patients, respectively. Regional lymph nodes were involved in 99 patients while non-regional lymph nodes were involved in 38 patients. Bone metastasis was present in 53 patients and visceral metastasis was present in 18 patients. 108 patients with localized/loco-regional disease underwent treatment with curative intent while 60 patients with metastatic disease underwent treatment with palliative intent. Overall, 88 patients underwent robotic radical prostatectomy, 20 underwent radical radiation therapy while 60 were treated with Androgen Deprivation Therapy (ADT alone -27 patients, ADT with docetaxel - 22 patients or ADT with abiraterone – 11 patients).Table: 230P

Clinico-radiological characteristics and treatment received

CharacteristicNumber =168 (%)
Median Age (years) (Range)67 (30-88)
Median PSA (ng/ml) (Range)30 (1-4000)
Gleason score
65 (2.9)
756 (33)
852 (31)
938 (23)
103 (2)
unknown14 (8)
Ga 68-PSMA PET/CT Findings
Tumour size T219 (11)
T389 (53)
T435 (21)
Regional lymph nodes99 (59)
Non-regional lymph nodes38 (23)
Bone metastasis53 (32)
Visceral metastasis18 (11)
Treatment Intent - Curative108 (64)
Radical Prostatectomy88 (52)
Radical Radiotherapy20 (12)
Treatment intent - palliative60 (36)
ADT alone27 (16)
ADT + docetaxel22 (13)
ADT + abiraterone11 (7)


Within the limitations of a retrospective study we conclude that 68Ga-PSMA PET/CT scan is a useful radiological test for staging of prostate cance. As experience with this modality grows, increasingly it is being employed in treatment decision making.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Max Institute of Cancer Care.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings